Epidermal growth factor receptor variant III (EGFRvIII) seems to constitute the perfect
therapeutic target for glioblastoma (GB), as it is specifically present on up to 28–30% of GB …

The epidermal growth factor receptor (EGFR) is dysregulated in various tumour types such
as glioblastoma multiforme (GBM), breast cancer, ovarian carcinoma, non-small cell lung …

Glioblastoma multiforme (GBM) is the most common brain tumour and has the worst
prognosis. Epidermal growth factor receptor (EGFR) gene amplification, mutation and re …

In epithelial tumors, the epidermal growth factor receptor (EGFR) controls key signaling
pathways responsible for growth, proliferation, migration, and survival of tumor cells. The …

The epidermal growth factor receptor (EGFR) is overexpressed in a variety of human
epithelial tumors, often as a consequence of gene amplification. Tumors with EGFR gene …

Amplification of epidermal growth factor receptor (EGFR) and its active mutant EGFRvIII
occurs frequently in glioblastoma (GBM). While EGFR and EGFRvIII play critical roles in …

Mutations in the epidermal growth factor receptor occur frequently in a number of human
tumours including gliomas, non-small-cell lung carcinomas, ovarian carcinomas and …

Alterations of the epidermal growth factor receptor (EGFR) occur frequently in malignant
gliomas through gene amplification or rearrangement, especially in a large fraction of de …

A truncation mutant of the epidermal growth factor receptor, EGFRvIII, is commonly
expressed in glioma, an incurable brain cancer. EGFRvIII is tumorigenic, in part, through its …

Purpose: We have reported previously that tumors expressing wild-type epidermal growth
factor receptor (EGFR) in a murine model are sensitive to the EGFR tyrosine kinase inhibitor …